Shopping Cart
- Remove All
Your shopping cart is currently empty
Zunsemetinib
🥰Excellent
Catalog No. T39126Cas No. 1640282-42-3
Alias CDD-450, ATI-450
Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis.
Zunsemetinib
🥰Excellent
Purity: 99.77%
Catalog No. T39126Alias CDD-450, ATI-450Cas No. 1640282-42-3
Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | 268 € | In Stock | |
| 5 mg | 654 € | In Stock | |
| 10 mg | 1.121 € | In Stock | |
| 25 mg | 1.672 € | In Stock | |
| 50 mg | 2.251 € | In Stock | |
| 100 mg | 3.021 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Zunsemetinib"
sodium lauroyl-α-hydroxyethyl sulfonate
T7283112714-99-5
Sodium houttuyfonate is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- 50 €
Size
QTY
NG25
Cited
T56431315355-93-1
NG25 is a potent dual inhibitor of TAK1 and MAP4K2, with IC50s of 149 nM and 21.7 nM, respectively.
- 75 €
Size
QTY
CitedCMPD1
T1498841179-33-3
CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).
- 29 €
Size
QTY
Vemurafenib Cited
RO5185426, RG7204, PLX4032
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- 47 €
Size
QTY
CitedSKLB-163
SKLB163
T261931255099-06-9In house
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
- 130 €
Size
QTY
Takinib Cited
EDHS-206
T42641111556-37-6
Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).
- 62 €
Size
QTY
CitedRV01
T127811016897-10-1
RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.
- 53 €
Size
QTY
Sodium lauryl sulfoacetate
Sodium houttuyfonate
T36031847-58-1
Sodium lauryl sulfoacetate (Sodium houttuyfonate) is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- 28 €
Size
QTY
Selonsertib Cited
GS-4997
T33501448428-04-3
Selonsertib (GS-4997) is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
- 31 €
Size
QTY
CitedMBM-55S
T119612083624-07-9In house
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
- 185 €
Size
QTY
Nomilin
T36721063-77-0
Nomilin is naturally occurring triterpenoids, have immunomodulatory activity.
- 37 €
Size
QTY
MK2-IN-3 hydrate
MK-2 Inhibitor III
T120581186648-22-5
MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM)
- 28 €
Size
QTY
Select Batch
Purity:99.77%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis. |
| In vitro | Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2, and inhibits in vitro osteoclast formation induced by RANKL.[1] Zunsemetinib (1 and 10 μM; 1h) decreases IL-1β expression by promoting IL-1β mRNA degradation and has no effect on NLRP3 expression.[1] Zunsemetinib (0.4 nM~1 μM; 16h; PBMC cells) reduces IL-1β secretion and promotes IL-1β mRNA instability.[1] |
| In vivo | Zunsemetinib (1,000 ppm; p.o.; 8-week-old WT female mice) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.[1] Zunsemetinib (10 and 20 mg/kg; p.o.) prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis and increases bone density.[1] |
| Alias | CDD-450, ATI-450 |
| Molecular Weight | 513.92 |
| Formula | C25H22ClF2N5O3 |
| Cas No. | 1640282-42-3 |
| Smiles | Cc1cnc(cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O)-c1ccnc(n1)C(C)(C)O |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (155.67 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Zunsemetinib | purchase Zunsemetinib | Zunsemetinib cost | order Zunsemetinib | Zunsemetinib chemical structure | Zunsemetinib in vivo | Zunsemetinib in vitro | Zunsemetinib formula | Zunsemetinib molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.